The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
01/12/2023
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes. Diabetes Obes Metab., 2023;25(5):1241-1248.
12/29/2022
ADOCIA Announces the Successful Phase 1 Study for BioChaperone® Lispro with Partner Tonghua Dongbao
12/01/2022
Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products
10/25/2022
ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates
10/06/2022
ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis
Investors Webinar of Sept 20th, 2022
09/15/2022
ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th
09/07/2022
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes
2022 AdoShell Islets Presentation
06/21/2022
ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes
05/18/2022
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
05/09/2022
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao
04/11/2022
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao
03/28/2022
Adocia strengthens its cash position by 19 million euros following a real estate transaction
10/14/2021
ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China
09/21/2021
ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD
07/29/2021
Bilan Semestriel du contrat de liquidité Adocia conclu avec la société Kepler Capital Markets
06/29/2021
ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
06/27/2021
ADO09, a coformulation of insulin A21G and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with T1D, Dr. Grégory Meiffren, June 27, 2021, ADA virtual event.
Join our mailing list. Subscribe